PortViewPortView
eXoZymes logo

eXoZymes (EXOZ) Stock Analysis

NASDAQHealthcareBiotechnology

$6.80+4.62%
1-year price historyRange $4.40 – $16.50
52-week range$6.80
$4.35$18.40

What eXoZymes does

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Key metrics

Market cap
$63.11M
P/E (TTM)
-5.91
EPS (TTM)
$-1.15
Beta
2.93
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$6.35
200-day avg
$9.43
52-week high
$18.40
52-week low
$4.35
CEO
Michael Heltzen

ETFs linked to EXOZ

Broad-market and Healthcare sector ETFs an investor holding eXoZymes is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EXOZ fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze EXOZ in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for eXoZymes?
eXoZymes trades under the ticker EXOZ on NASDAQ.
Which exchange is EXOZ listed on?
EXOZ is listed on NASDAQ.
What sector does eXoZymes operate in?
eXoZymes is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze EXOZ in a portfolio?
PortView shows EXOZ's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.